IMUGENE LIMITED — Regulatory Filings 2013

Mar 4, 2013

==> picture [227 x 49] intentionally omitted <==

Imugene

to be awarded Japanese patent for novel drug delivery technology

Highlights

•  Japan Patent Office accepts key foundation patent application protecting Imugene’s Linguet™ drug delivery technology

•  Patent protects specific drug formulations targeting bone loss prevention

•  Patent will supplement Imugene’s current focus in creating a novel treatment for Vitamin D deficiency

Melbourne, 5 March 2013: Australian drug delivery technology company Imugene (ASX.IMU) has announced today the acceptance of a key Japanese patent application for the Company’s novel drug delivery technology Linguet™.

The Japanese application provides protection around Linguet’s™ formulations and other specific excipients for a class of drugs that prevent the loss of bone mass, known as bisphosphonic acids and bisphosphonates, which are used to treat conditions such as osteoporosis and multiple myeloma.

Imugene’s novel Linguet™ technology enables the active ingredient of drugs to be absorbed straight into the bloodstream when placed inside the cheek (via the buccal mucosa) or under the tongue (sublingual). The proprietary tablet can improve the efficacy and safety of a range of prescription and over the counter medicines, with the Company’s first target being Vitamin D deficiency.

“I am extremely pleased to secure allowance of a key patent application for Linguet™ in a major regulatory market like Japan. As we work towards generating early revenues from our novel Vitamin D dosage form, this new patent will allow us to investigate the potential for our Vitamin D target, a key factor in promoting calcium absorption, to be combined with bisphosphonates used to treat bone loss, and expand its commercial appeal,” said Dr Nick Ede, Executive Director of Imugene.

Over the past six months Imugene has completed feasibility testing and formulation development for a novel rapid Linguet™ form of Vitamin D and is expecting to file for regulatory approval in the UK in 2014.

Vitamin D deficiency is a major public health concern, and affects 31% of all Australian adults – and more than 1 billion people worldwide - and is associated with a wide range of conditions including pre-diabetes, osteoporosis, cardiovascular health and prostate cancer.

Current oral Vitamin D supplements are absorbed through the gastro-intestinal tract erratically and lead to momentary surges of Vitamin D in the blood stream, limiting the effectiveness of the treatment. In contrast, Imugene’s Vitamin D formulation is designed to

be absorbed directly into the blood stream to deliver a controlled dose which can restore circulating Vitamin D levels more rapidly, effectively and safely.

For enquiries please contact:

Dr Nicholas Ede, Imugene, +61 (0)400 642 254 or email nede@imugene.com

Kyahn Williamson, Buchan Consulting +61 3 9866 4722 or email kwilliamson@buchanwe.com.au

About Imugene

Imugene Limited (ASX:IMU) is commercialising drug delivery applications based on its novel buccal (drugs administered via the cheek) Linguet™ technology. Linguet™ is a patient friendly and cost effective system used to deliver established pharmaceutical and nutraceutical products.